When Can Exparel Generics Be Launched?
The market exclusivity for Pacira Biosciences' Exparel (bupivacaine liposome injectable emulsion) is set to expire in 2025 [1]. This expiration marks a key date for potential generic competition.
What Factors Influence Generic Entry for Exparel?
Several factors will determine the timeline for generic competition. These include the expiration of relevant patents and any existing market exclusivities granted by regulatory bodies [1]. DrugPatentWatch.com tracks these patent and exclusivity expirations for pharmaceutical products [1].
What Patents Protect Exparel?
Pacira Biosciences holds several patents related to Exparel. The most critical patent for Exparel's market exclusivity is U.S. Patent No. 8,901,076, which covers the formulation of bupivacaine liposome [1]. This patent is scheduled to expire in 2025 [1]. Other patents related to Exparel's manufacturing and use also exist [1].
Could Exparel Face Litigation Regarding Patents?
It is common for pharmaceutical companies to defend their patents through litigation, and Exparel may face such challenges. Companies seeking to launch generic versions often challenge existing patents, citing invalidity or non-infringement [1]. Information regarding ongoing or past litigation concerning Exparel's patents can be found through patent tracking services [1].
What Are the Timelines for Generic Drug Approvals?
Following patent expiration, generic drug manufacturers must submit an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval [2]. The FDA reviews ANDAs to ensure that the generic drug is bioequivalent to the branded drug and meets all quality standards. The approval process can take several months to a few years, depending on the complexity of the application and FDA workload [2].
Who Are Potential Competitors for Exparel Generics?
Potential competitors would be generic drug manufacturers that specialize in producing injectable anesthetics. Once patent protection and market exclusivity expire, these companies can seek FDA approval to market their versions of Exparel [1][2].
What is the Role of Market Exclusivity Beyond Patents?
Regulatory bodies like the FDA can grant periods of market exclusivity that are independent of patent protection. For example, new chemical entities typically receive five years of exclusivity, while certain other exclusivities exist for different circumstances [3]. Understanding these various exclusivities alongside patent expiries is crucial for predicting generic entry [1][3].
How Does Exparel Work?
Exparel is a long-acting local anesthetic that utilizes DepoFoam technology [4]. This technology encapsulates the anesthetic bupivacaine within a lipid-based matrix, allowing for sustained release over an extended period [4]. It is used to provide post-surgical analgesia, reducing the need for opioid pain medications [4].
Sources:
[1] DrugPatentWatch.com
[2] U.S. Food and Drug Administration
[3] U.S. Food and Drug Administration, Hatch-Waxman Act and Generic Drugs
[4] Pacira Biosciences, Exparel Product Information